Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST266 in allergic conjunctivitis
NCT02978183Phase 2Completed
- Sponsor
- Noveome Biotherapeutics
- Start
- Dec 2016
- Primary completion
- Feb 2017
- Modality
- Cytokines & Interferons, Hormones & Growth Factors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic conjunctivitis (AC) comparing ST266 with Placebo (2 arms). Primary endpoints: Ocular Itching at Day 8 and Conjunctival Redness at Day 8. Started Dec 2016; status: completed.
02
Drugs
ST266
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02978183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978183.